States Challenge New Federal Restrictions on Title X Family Planning Grants

States Move to Block New Conditions on Title X Family-Planning Funds

A coalition of 23 state attorneys general — including New Jersey's Jennifer Davenport — is suing to stop new federal conditions the Trump Administration has attached to Title X grants, arguing the rules would gut access to contraception, cancer screenings, STI testing and treatment, and other preventive services for low-income patients.

What the New Conditions Would Require

The disputed conditions apply to the 2027–2032 Title X grant cycle and were announced in July. Pennsylvania Governor Josh Shapiro filed a separate lawsuit against the Department of Health and Human Services on August 27 over the same rules, with state officials warning that grantees would have to choose between rewriting their programs to fit federal political priorities or submitting applications that risk being rejected.

According to the Shapiro administration, the new conditions would push grantees to end programs that promote health equity or serve transgender and intersex patients; eliminate what HHS categorizes as "overmedicalization" — a category state officials say includes hormonal contraception; adopt "life-affirming" program delivery; and use directive counseling that steers patients toward parenthood and marriage. The underlying complaint is that these requirements have little to do with the public-health purpose of Title X, which for more than 50 years has been the only federal funding stream dedicated to family planning for people who are uninsured or underinsured.

What Patients Should Watch Now

Title X dollars flow quietly through local clinics, county health departments, and community providers — the same places many patients first access contraception, Pap testing, and confidential STI services. If the rules take effect, the practical question for patients is whether their usual clinic will still be able to offer the full range of those services using federal support, whether some sites may drop out of the program rather than reshape their care model, and whether waitlists or costs could shift.

The lawsuits are only the opening round. Until a court blocks the conditions or HHS reconsiders, clinics face uncertainty about what their 2027 applications can promise to deliver. Readers who depend on a Title X-funded site — especially for contraception, cervical cancer screening, or STI care — should ask their provider, in concrete terms, whether their current services are expected to continue, what would change if federal funding is restricted, and whether the clinic has a contingency plan. As the litigation unfolds, local advocacy organizations remain the most reliable source of real-time updates on which services in your area are unaffected, scaled back, or actively at risk.